Ipca Laboratories Q2 FY27: revenue up 13.8% to ₹2,910 Cr, net profit up 32.8% to ₹375 Cr
Results · Finvezto · 5 Nov 2026 · Ipca Laboratories (IPCALAB)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 2,910 | - | +13.8% |
| Operating profit | 674 | - | +23.6% |
| Net profit | 375 | - | +32.8% |
| Operating margin | 23.1% | - | +1.8 pp |
| Net margin | 12.9% | - | +1.8 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Consolidated revenue for Q2 FY27 grew 14% year-on-year to INR 2,910 crores, driven by 14% growth in domestic formulations and 32% growth in standalone export formulations. Earnings call
- Consolidated EBITDA margin expanded to 22.97% from 21.68% in Q2 FY26, despite elevated input costs, shipping rates, and energy expenses. Earnings call
- Management reiterated its FY27 guidance of 14% to 16% revenue growth and 22% to 23% consolidated EBITDA margin. Earnings call
What to watch
- Management on consolidated ebitda margin guidance: And consolidated EBITDA margin guidelines was from 22% to 23%, that will also stand there.
- Management on domestic branded business growth: So we maintain our guidelines of 15% to 16% growth overall in India.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.